Previous 10 | Next 10 |
Enochian BioSciences ( NASDAQ: ENOB ) said Thursday it got a notice from Nasdaq stating that the company remains in non-compliance with the exchange's listing rules for not filing its Form 10-Q for the period ended December 31, 2022. The notification has no immediate effect on the...
LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended ...
LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended Septe...
LOS ANGELES, Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world’s deadliest diseases. Last week, the Company announced its oncology pl...
Enochian BioSciences ( NASDAQ: ENOB ) received a notice from The Nasdaq that it is no longer in compliance with its rule as the company had not yet filed its Form 10-K. The Company has 60 calendar days to either file the Form 10-K or to submit to Nasdaq a plan to regain co...
LOS ANGELES, Oct. 21, 2022 (GLOBE NEWSWIRE) -- On October 17, 2022, Enochian BioSciences, Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-K, the Company is no longer in complianc...
Enochian BioSciences ( NASDAQ: ENOB ) stock rose ~5% on Monday after the company said that it received a U.S. patent for its proprietary cancer treatment platform which could potentially be used to induce life-long remission. Preclinical animal and laboratory ...
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Today, Enochian BioSciences (the Company) announced that it was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world’s deadliest solid tum...
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP reminds investors who purchased Enochian Biosciences Inc. (“Enochian” or the “Company”) (NASDAQ: ENOB) common stock between February 16, 2018, and June 27, 2022, inclusive (the ...
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP reminds investors who purchased Enochian Biosciences Inc. (“Enochian” or the “Company”) (NASDAQ: ENOB) common stock between February 16, 2018, and June 27, 2022, inclusive (the ...
News, Short Squeeze, Breakout and More Instantly...
Enochian Biosciences Inc. Company Name:
ENOB Stock Symbol:
NASDAQ Market:
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the “Annual Meeting”), which was sched...